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The activity of the RAF/MEK/ERK signaling pathway is
critical for the proliferation of normal and cancerous cells.
Oncogenic mutations driving the development of lung
adenocarcinoma often activate this signaling pathway. In
contrast, pathway activity levels and their biological roles
are not well established in small cell lung cancer (SCLC), a
fast-growing neuroendocrine lung cancer subtype. Here we
discuss the function of the RAF/MEK/ERK kinase pathway
and the mechanisms leading to its activation in SCLC cells.
In particular, we argue that activation of this pathway may
be beneﬁcial to the survival, proliferation, and spread of
SCLC cells in response to multiple stimuli. We also consider
evidence that high levels of RAF/MEK/ERK pathway activity
may be detrimental to SCLC tumors, including in part
by interfering with their neuroendocrine fate. On the basis
of these observations, we examined when small molecules
targeting kinases in the RAF/MEK/ERK pathway may be
useful therapeutically in patients with SCLC, including in
combination with other therapeutic agents.
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Extracellular signal–regulated kinases 1 and 2
(ERK1/2) are serine/threonine-selective protein kinases
involved in the regulation of fundamental biological
processes such as proliferation, survival, and differenti-
ation. ERK1/2 are viewed as canonical mitogen-activated
protein kinases (MAPKs) with cytoplasmic and nuclear
substrates involved in signal transduction and the
regulation of transcription. These two kinases playredundant roles in proliferation and growth.1 ERK1/2
are activated through phosphorylation by upstream
MAPK/ERK kinases MAPK/ERK kinase 1 and 2 (MEK1/
2), which are tyrosine/threonine protein kinases that are
also essential for development and normal proliferation
in adult cells.2,3 The RAF family of serine/threonine
protein kinases (RAF-1, B-RAF, and A-RAF) activates
MEK1/2 by phosphorylation. This RAF/MEK/ERK
signaling module is under the control of RAS guanosine
triphosphatases and a number of growth factor re-
ceptors, including epidermal growth factor receptor
(EGFR) (reviewed in Roskoski 4). Mutations that activate
the RAF/MEK/ERK signaling pathway are found in a
large fraction of human cancers, including lung adeno-
carcinoma,5 in which they are thought to be key drivers.
These observations have led to the development of small
molecules targeting these kinases, including U.S. Food
and Drug Administration–approved inhibitors of RAF
and MEK kinases (reviewed in Caunt et al.,6 Holderﬁeld
et al.,7 and Deuker and McCormick8) (Fig. 1A).
Small cell lung carcinoma (SCLC) is an aggressive form
of neuroendocrine lung cancer that accounts for approx-
imately 15% of all lung cancer cases. The median survival
time of patients in whom SCLC has been diagnosed is a
bleak 6 to 12 months. SCLC tumors are often initially
responsive to chemotherapy, but they relapse within 2 to
6 months, almost without exception. At this point, fewJournal of Thoracic Oncology Vol. 11 No. 8: 1233-1241
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Figure 1. (A) Schematic representation of the canonical RAS-MEK-ERK pathway and its upstream activators relevant to small
cell lung cancer (SCLC) (see text). Speciﬁc small molecule inhibitors are available for each kinase in this pathway. All these
activators of extracellular signal–regulated kinases 1 and 2 (ERK1/2) activity may have some beneﬁcial effects for the tumors.
(B) Expression of genes coding for members of the canonical RAS/RAF/MEK/ERK pathway in human SCLC tumors (RNA-Seq
data from George et al.9). All the genes are expressed at detectable levels, with lower levels for epidermal growth factor
receptor gene (EGFR) and v-Raf murine sarcoma viral oncogene homolog B, serine/threonine kinase gene (BRAF). Achaete-
scute family bHLH transcription factor 1 gene (ASCL1), chromogranin A gene (ChgA) and enolase 2 gene (ENO2) (neuron-
speciﬁc enolase) are classical neuroendocrine markers for SCLC. FGF2, ﬁbroblast growth factor 2; IGF1, insulin-like growth
factor 1; SCF, stem cell factor; EGF, epidermal growth factor; FGFR, ﬁbroblast growth factor receptor; IGFR, insulin-like
growth factor receptor; EGFR, epidermal growth factor receptor; RTK, receptor tyrosine kinase; GPCR, G protein–coupled
receptor; FDA, U.S. Food and Drug Administration; MEK, mitogen-activated protein kinase/extracellular signal–regulated
kinase kinase; KRAS, Kirsten rat sarcoma viral oncogene homolog gene; NRAS, neuroblastoma RAS viral (v-ras) oncogene
homolog gene; ARAF, A-Raf proto-oncogene, serine threonine kinase gene; RAF1, Raf-1 proto-oncogene, serine/threonine
kinase gene; FKPM, fragments per kilobase of transcript per million mapped reads.
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cumbwith multiple metastases. Because of the aggressive
time line and invariable resistance to standard chemo-
therapy of SCLC, a major goal in the ﬁeld has been to
identify more pharmacological targets to enable novel
therapies for the approximately 200,000 patients world-
wide who die of this disease each year.12,13 Recent cancer
genomic efforts have identiﬁed the landscape ofmutations
in SCLC.9,14,15 The tumor suppressors RB and P53 are
inactivated in almost all SCLC tumors. Most of the other
mutations found in human SCLC are also loss-of-function
events (e.g., inactivating mutations in Notch receptors9),
whereas targetable mutations occur in very rare cases.9
Here we discuss the activity and the possible roles of
the RAF/MEK/ERK signaling pathway in SCLC cells,
focusing on the possible therapeutic use of inhibitors of
this kinase module in patients.Evidence Pointing to Detrimental Effects
of RAF/MEK/ERK Signaling Activation for
the Growth of Neuroendocrine SCLC
Nearly three decades ago, it was reported that levels
of the EGFR receptor were low in human SCLC speci-
mens,16 suggesting that high level and activity of this
receptor may not be selected for in SCLC cells. Indeed,
an analysis of recent RNA-Seq data sets from human
SCLC conﬁrms very low transcript levels for this re-
ceptor9 (Fig. 1B). In addition, activating mutations in
oncogenes signaling through the RAS/RAF/MEK/ERK
pathway are rare in SCLC tumors9,14,15 (Fig. 2). Simi-
larly, recent observations in EGFR mutant lung ade-
nocarcinomas that transform to SCLC in response to
EGFR inhibition show a signiﬁcant decrease in the
expression of this receptor during the reprogramming
Gene Name % Altered Significantly Altered in Study?
Peifer et al. Rudin et al. George & Lim et al.
TP53 79-98 3 3 3
RB1 35-91 3 3 3
ZDBF2 23 3
TMEM132D 23 3
COL22A1 18-22 3 3
CREBBP 15-17 3 3
EP300 10-13 3 3
RIMS2 20 3
KIAA1211 18 3
FMN2 18 3
BCLAF1 18 3
SLIT2 17 3
NOTCH1 15 3
TP73 13 3
KIF21A 12 3
DIP2C 12 3
ELAVL2 12 3
RUNX1T1 12 3
ASPM 12 3
ALMS1 11 3
GRIK3 11 3
MLL 10 3
COBL 10 3
EPHA7 10 3
RGS7 10 3
PDE4DIP 10 3
CNTNAP2 10 3
COL4A2 10 3
NOTCH3 9 3
PTEN 9 3
ADCY1 8 3
XRN1 8 3
RASSF8 7 3
CDYL 7 3
FPR1 6 3
RBL1 6 3
RBL2 6 3
KIT 6 3
GRM8 6 3
PLSCR4 6 3
SATB2 5 3
PTGFRN 5 3
NOTCH2 5 3
KHSRP 4 3
NOTCH4 3 3
PIK3CA 3 3
BRAF 3 3
C17orf108 2 3
Gene Name Amp or Del? Significant CNV in Study?
ANKHD1 Deletion 3
CACNA2D3 Deletion 3
CDKN2A Deletion 3
CNTN3 Deletion 3
ESCO2 Deletion 3
FHIT Deletion 3 3 3
KIF2A Deletion 3
RASSF1 Deletion 3
RB1 Deletion 3 3 3
TP53 Deletion 3
CCNE1 Amplification 3
FGFR1 Amplification 6% 3
IRS2 Amplification 2%
MYC Amplification 2% 3
MYCL1 Amplification 8% 3 3
MYCN Amplification 6% 3 3
NADKD1 Amplification 3
SOX2 Amplification 27%
SOX4 Amplification 3
URI1 Amplification 3
A B
Peifer et al. Rudin et al. George & Lim et al.
Figure 2. Summary of gene alterations (A) and copy number variations (CNVs) (B) in human primary small cell lung cancer
from three genomics studies.9,14,15 Note the rarity of alterations in upstream regulators of extracellular signal–regulated
kinases 1 and 2. TP53, tumor protein p53 gene; RB1, retinoblastoma 1 gene; ZBDF2, zinc ﬁnger DBF-containing 2 gene;
TMEM132D, transmembrane protein 132D gene; COL22A1, collagen type XXI alpha 1 gene; CREBBP, CREB binding protein
gene; EP300, E1A binding protein p300 gene; RIMS2, regulating synaptic membrane exocytosis 2 gene; KIAA1211, KIAA1211
gene; FMN2, formin 2 gene; BCLAF1, BCL associated transcription factor 1; SLIT2, slit guidance ligand 2 gene; NOTCH1, notch
1 gene; TP73, tumor protein p73; KIF21A, kinesin family member 21A gene; DIP2C, disco interacting protein 2 homolog C
gene; ELAVL2, ELAV like neuron-speciﬁc RNA protein binding 2 gene; RUNX1T1, RUNX1 translocation partner 1 gene; ASPM,
abnormal spindle microtubule assembly gene; ALMS1, ALMS1, centrosome and basal body associated protein gene; GRIK3,
glutamate ionotropic receptor kainate type subunit 3 gene; MLL, mixed-lineage leukemia gene; COBL, cordon-bleu WH2
repeat protein gene; EPHA7, EPH receptor A7 gene; RGS7, regulator of G-protein signaling 7 gene; PDE4DIP, phosphodies-
terase 4D interacting protein gene; CNTNAP2, contactin associated protein-like 2 gene; COL4A2, collagen type IV alpha 2
gene; NOTCH3, notch 3 gene; PTEN, phosphatase and tensin homolog gene; ADCY1, adenylate cyclase 1 (brain); XRN1, 50-30
exoribonuclease 1 gene; RASSF8, Ras association domain family member 8 gene; CDYL, chromodomain protein, Y-like gene;
FPR1, formyl peptide receptor 1 gene; RBL1, retinoblastoma-like 1 gene; RBL2, retinoblastoma-like 2 gene; KIT, KIT proto-
oncogene receptor tyrosine kinase gene; GRM8, glutamate metabotropic receptor 8 gene; PLSCR4, phospholipid scramblase 4
gene; SATB2, SATB homeobox 2 gene; PTGFRN, prostaglandin F2 receptor inhibitor gene; NOTCH2, notch 2 gene; KHSRP, KH-
type splicing regulatory protein gene; NOTCH4, notch 4 gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase cat-
alytic subunit alpha gene; BRAF, B-Raf proto-oncogene, serine/threonine kinase; C17orf108, chromosome 17 open reading
frame 108 gene; ANKHD1, ankyrin repeat and KH domain containing 1 gene; CACNA203, calcium voltage-gated channel
auxiliary subunit alpha2delta 3 gene; CDKN2A, cyclin-dependent kinase inhibitor 2A gene; CNTN3, contactin 3 gene; E3SCO2,
establishment of sister chromatid cohesion N-acetyltransferase 2 gene; FHIT, fragile histidine triad gene; KIF2A, kinesin
heavy chain member 2A gene; RASSF1, Ras association domain family member 1 gene; CCNE1, cyclin E1; FGFR1, ﬁbroblast
growth factor receptor 1 gene; IRS2, insulin receptor substrate 2 gene; MYC, v-myc avian myelocytomatosis viral oncogene
homolog gene; MYCL1, v-myc avian myelocytomatosis viral oncogene lung carcinoma derived homolog gene; MYCN, v-myc
avian myelocytomatosis viral oncogene neuroblastoma derived homolog gene; NADKD1, NADKD1 antisense RNA 1 gene; SOX2,
SRY-box 2 gene; SOX4, SRY-box 4 gene; UR11, URI prefoldin-like chaperone gene.
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RAF/MEK/ERK pathway may be selected against in
SCLC cells comes from the observation that the c-RAF-1
oncogene is located at chromosome 3p25, near a region
that is often deleted in SCLC tumors9; thus a number of
SCLC cells may be hemizygous for c-RAF-1 and might
therefore have lower RAF activity.18,19 One interpre-
tation of these ﬁndings is that the RAF/MEK/ERK
pathway is not highly active in SCLC, especially in
comparison to lung adenocarcinoma, in which acti-
vating mutations upstream in the pathway are
frequent.5 Indeed, an attempt to quantitatively assay
MAPK activity by proteomics identiﬁed a 1.9-fold
decrease in the activation of ERK in SCLC cell lines
compared with in non–small cell lung cancer cell lines
in culture.20
In fact, evidence suggests that a lack of pathway
activity may be advantageous to SCLC tumors.
Although phosphorylated ERK1/2 can be detected in
48% of SCLC tumors in histological studies, speciﬁcally
cytoplasmic expression of this active form of the
ERK1/2 kinases has been linked to better patient
survival.21 This suggests that decreased phospho-
Erk1/2 in tumors may correlate with faster progres-
sion. A second study found 24% of SCLC tumors
positive for phospho-ERK1/2, but no correlation was
found with disease-free or overall survival, possibly
because this study did not distinguish cytoplasmic and
nuclear signals.22
Furthermore, induction of activated RAF-1 (c-RAF) in
human SCLC cells causes growth arrest.23,24 Expression
of high levels of oncogenic RAS can further result in a
reduction in cell proliferation, which is accompanied by
a loss of neuroendocrine features. Even in the long term,
when cells adapt to this inhibitory effect, they form tu-
mors with nonneuroendocrine features, suggesting that
high RAF/MEK/ERK activity is not compatible with a
neuroendocrine cell fate in SCLC.25 Similarly, acute
activation of Notch signaling in SCLC cells results in a
cell cycle arrest accompanied by a marked increase in
ERK1/2 activation26 and a consequent loss of neuroen-
docrine features.9 Some of these experiments involve a
great level of hyperactivation of the RAF/MEK/ERK
pathway, which may or may not be physiologically
relevant, but these results support the idea that high
activity of ERK1/2 downstream of the RAF/MEK/ERK
pathway can be detrimental to cycling neuroendocrine
SCLC cells.
The rarity of mutations in upstream activators of
ERK1/2 in SCLC tumors and the detrimental effects of
ectopic pathway activation in these neuroendocrine tu-
mor cells have led to the idea that the activity of the
RAF/MEK/ERK signaling pathway must remain low in
SCLC cells for optimal tumor growth.Activation of RAF/MEK/ERK Signaling
Downstream of Receptor Tyrosine
Kinases Can Promote Proliferation and
Survival in SCLC Cell Populations
Although genetic proﬁling of SCLC shows mutations
in ERK1/2 activators to be very rare and experimental
data suggest that strong pathway activation in SCLC cells
causes growth arrest, signaling through this pathway
has, in some contexts, been shown to promote cell sur-
vival and growth. This suggests that signaling through
core MAPK members and upstream receptor tyrosine
kinases is not just a remnant of incomplete silencing or
loss, but is in fact functional and may be advantageous
for cellular growth and survival (see Fig. 1A).
EGFR is a core receptor upstream of the MAPK kinase
axis. Even though, as already stated, EGFR levels are low
in SCLC, the expression of this receptor tyrosine kinase is
detectable in some cell lines. In such cells, inhibition of
EGFR activity can abrogate phosphorylation of ERK1/2
upon stimulation with EGF, suggesting that the EGFR/
RAS/RAF/MEK/ERK pathway can be functional in
SCLC cells.27 Unfortunately, in clinical trials in patients
with SCLC, single-agent EGFR inhibitors have shown
no activity.28,29 EGFR activity in tumors correlates
with phospho-ERK1/2 signal but also with activated
mammalian target of rapamycin, suggesting that
mammalian target of rapamycin inhibitors may enhance
the effects of EGFR inhibitors, which has been validated
in culture22 and may instruct future clinical trials.
Although activating mutations in oncogenes signaling
through the RAS/RAF/MEK/ERK pathway are rare in
SCLC tumors, such mutations have been identi-
ﬁed.9,14,15,30,31 For example, activating mutations in the
c-KIT receptor are present in a small percentage of hu-
man SCLC tumors9,32 (see Fig. 2), and activation of this
receptor by its ligand stem cell factor can promote
ERK1/2 activity in SCLC cells,33–36 although in certain
contexts SCLC cells respond to stem cell factor binding
independently of ERK1/2.37
Ampliﬁcation of insulin receptor substrate 2 gene
(IRS2), a gene coding for a signaling molecule down-
stream of several receptor tyrosine kinases including
insulin-like growth factor receptor 1 (IGF-1R), can be
detected in approximately 2% of human SCLC cases9
(see Fig. 2). Cotargeting of IGF-1R and c-KIT inhibits
phospho-ERK1/2 and can block the growth of H209
SCLC cells.38 As a single agent, IGF-1R inhibitors may
have some activity in a subset of SCLC tumors. Inter-
estingly, resistance to these inhibitors correlates with
increased phospho-ERK1/2 levels, suggesting that the
RAF/MEK/ERK pathway is a key mediator of IGF-1/IGF-
1R signaling in SCLC cells39 and raising the possibility
that a combination therapy inhibiting MEK activity could
August 2016 MAPK Signaling in SCLC 1237enhance the antitumor effects of an anti–IGF-1R mono-
clonal antibody.40 This combination therapy may be
especially valid given data in lung adenocarcinoma cells
indicating that IGF-1 and IGF-1R are important for the
emergence of drug tolerance after inhibition of the up-
stream MAPK signaling pathway by an EGFR inhibitor.41
Focal ampliﬁcations of the gene coding for the
ﬁbroblast growth factor receptor 1 (FGFR1) receptor
tyrosine kinase have also been found in tumors of pa-
tients with SCLC14,42 (see Fig. 2), and inhibition of FGFR
in xenograft models can impede tumor growth.43 The
FGF2 ligand promotes the expansion of SCLC cells44 and
can induce the translation of prosurvival factors through
a MEK-dependent pathway in these cells.45 Furthermore,
downregulation of B-RAF abolishes FGF2-mediated sur-
vival in SCLC cells.46 Several phase I and phase II clinical
trials testing the effects of FGFR inhibitors on patients
with SCLC are currently ongoing (see ClinicalTrials.gov
website [https://clinicaltrials.gov/]), and it is possible
that a fraction of patients with SCLC will beneﬁt from
this treatment option.
A number of molecules signaling through receptor
tyrosine kinases can therefore promote the growth of
SCLC cells in culture, and this phenotype correlates with
activation of ERK1/2 and can be suppressed in several
cases by MEK1/2 inhibition. These observations illus-
trate that activation of the RAF/MEK/ERK pathway can
have protumorigenic effects in SCLC cells. The difference
between this set of experiments and previously dis-
cussed experiments in which activation of ERK1/2 ac-
tivity is harmful to SCLC cells is unclear but may depend
on the context or levels of activation, with high levels
being disadvantageous but some activity being favorable.Activation of RAF/MEK/ERK Signaling
Downstream of GPCRs Can Promote
Proliferation and Survival of SCLC Cells
Various neuropeptides, such as galanin, neurotensin,
bradykinin, vasopressin, and bombesin, which promote
the clonal growth of SCLC cells in culture, induce activation
of ERK1/2. In particular, galanin and neurotensin can
stimulate ERK1/2 activation in SCLC cells through protein
kinase C, phospholipase C beta, and MEK1/2.47–49 Com-
parable results have been observed with bradykinin,50
oxytocin and vasopressin,51 and growth hormone–
releasing hormone.52 Similarly, gastrin-releasing peptide,
whose role as an autocrine factor in SCLC is well estab-
lished, can stimulate ERK1/2 activity in SCLC cells.53 All
these peptides signal in cells through speciﬁc G protein–
coupled receptors (GPCRs) and often work through auto-
crine or paracrine mechanisms, indicating that signaling
through ERK1/2 stimulation can promote the expansion
of SCLC cells (reviewed in Heasley54 and Moody et al.55).Nicotine has been found to elicit its stimulatory effect
on ERK1/2 activity in SCLC cells indirectly by inducing
the production or release of a factor that acts through a
pertussis toxin– and tyrosine kinase–sensitive route.56
Similarly, responses to nicotine-derived nitrosamine
ketone (a nitrosamine) are mediated by nicotinic
receptor–initiated release of serotonin and nicotine-
derived nitrosamine ketone–induced DNA synthesis
can be inhibited by a MEK inhibitor in SCLC cells57; this
activation of ERK1/2 by nicotine and nicotine-derived
nitrosamine ketone is true both in SCLC cells and wild-
type pulmonary neuroendocrine cells in culture,58 indi-
cating that these effects are not speciﬁc to transformed
neuroendocrine cells (reviewed in Schuller59).
SCLC cells can synthesize a number of neurotrans-
mitters that may promote the survival and growth of
SCLC in an autocrine manner.60,61 In particular, SCLC
cells produce acetylcholine, which acts as an autocrine
growth factor through both nicotinic and muscarinic
cholinergic mechanisms. The inhibitory effects of
muscarinic acetylcholine receptor antagonists correlates
with decreased ERK1/2 phosphorylation in tumors
growing in immunocompromised mice,62 suggesting that
the effects of neurotransmitters on SCLC may be at least
in part mediated by the RAF/MEK/ERK pathway.
In conclusion, accumulating evidence indicates that
activation of various GPCRs promotes the survival and
proliferation of SCLC cells. Some of these effects are
mediated by activation of the core RAF/MEK/ERK
pathway, suggesting that this module, although marked
by low activity in baseline conditions, can be activated in
response to autocrine and paracrine signals in the tumor
microenvironment.A Possible Role for RAF/MEK/ERK
Signaling in SCLC Metastasis
Emerging evidence suggests that in addition to hav-
ing a possible role in survival and proliferation, activa-
tion of the RAF/MEK/ERK pathway can promote cell
invasion and metastasis in SCLC cells (Fig. 3). Immuno-
histochemical analysis of primary tumor samples from
patients with SCLC has revealed high expression of the
GPCR chemokine receptor C-X-C chemokine receptor
type 4; the C-X-C motif chemokine 12 ligand can elicit
endocytosis of C-X-C chemokine receptor type 4, actin
polymerization, and robust activation of phospho-ERK1/
2 in SCLC cells, which correlates with a signiﬁcant in-
duction of invasive properties.63 In addition, paracrine
signaling through FGF2 from nonneuroendocrine SCLC
cells can activate ERK1/2 in neuroendocrine SCLC cells,
causing increased expression of the PEA3 (polyomavirus
enhancer activator 3 homolog) transcription factor and
subsequent metastatic dissemination of neuroendocrine
FGF2
FGFR CXCR4
ERK
PEA3
invasion,
metastasis
paracrine signal from
non-neuroendocrine
SCLC cells
paracrine signal from
stromal cells
CXCL12
ERK
cell migration,
adhesion to stroma
HGF
c-MET
ERK
paracrine and autocrine
signals?
cell migration,
invasion
Figure 3. Signaling networks that activate the canonical RAF/MEK/ERK signaling pathway and have been involved in small
cell lung cancer metastasis (see text). FGF2, ﬁbroblast growth factor 2; CXCL12, C-X-C motif chemokine 12; HGF, hepatocyte
growth factor; FGFR, ﬁbroblast growth factor receptor; CXCR4, C-X-C chemokine receptor type 4; ERK, extracellular signal–
regulated kinase; PEA3, polyomavirus enhancer activator 3 homolog.
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ceptor by its ligand hepatocyte growth factor activates
several signaling pathways, including ERK1/2 and the
proinvasion effects of hepatocyte growth factor/c-MET
correlate with ERK1/2 activation.65,66
Although this idea will require further testing in
preclinical models, these preliminary experiments sug-
gest that one of the most clinically relevant aspects of
RAF/MEK/ERK pathway activation in SCLC may be the
promotion of invasion and metastasis.
Conclusions
Early experimental evidence has suggested a model in
which RAF/MEK/ERK pathway activation may not play
an oncogenic role and may even be tumor suppressive in
SCLC. Nevertheless, we have not found evidence in the
literature suggesting that, as in the case of mouse em-
bryonic stem cells, long-term growth and the self-renewal
of SCLC cells could be enabled by the elimination of
ERK1/2 activity.67 Rather, a number of independent
studies have identiﬁed many stimuli whose signaling
through receptor tyrosine kinases, G-protein coupled
receptors, or other mechanisms68–71 can be mediated
through ERK1/2 activation in SCLC cells. Reconcilingthese somewhat paradoxical data seems to require a
model in which ERK1/2 activity must exist at some level
in SCLC and must have a dynamic range that allows
integration of signals through its activation but cannot
rise above a certain threshold. Testing this model may
require time-lapse imaging of single cells with reporters
measuring the activity of RAF/MEK/ERK pathway ki-
nases under different conditions, allowing us to decode
ERK1/2 activity in SCLC cells. A system allowing incre-
mental activation of the pathway may also help elucidate
a switch in activation level that may be mutually exclu-
sive with a neuroendocrine cell identity.
Genomic studies suggest that targeting RAF/MEK/
ERK pathway members or their upstream regulators
may not be clinically signiﬁcant, except in the few cases
in which genes coding for these molecules are mutated
in SCLC tumors. However, following the principle of
“nononcogene addiction,”72 some factors and pathways
can be essential for the growth and maintenance of tu-
mors without being genetically altered. Thus, it is
entirely possible that RAF/MEK/ERK pathway inhibition
in SCLC thus far has had limited effects simply on ac-
count of the strong cytotoxicity of inhibitors in this
pathway.73 Emerging research additionally suggests that
August 2016 MAPK Signaling in SCLC 1239RAF/MEK/ERK pathway inhibition may block a number
of prometastatic mechanisms in SCLC cells. Thus, RAF or
MEK1/2 inhibitors may be particularly useful in patients
with localized disease or with few metastases that could
be removed surgically to help delay the appearance of
new metastatic lesions.
Perhaps more clinically relevant would be the use of
inhibitors of the RAF/MEK/ERK pathway in combination
therapies, including immunotherapies.74 In addition to a
number of examples already discussed in this article,
emerging evidence would suggest that such inhibitors
could be useful in combination with Bcl-275,76 and heat
shock protein 90 inhibitors.77 In these contexts, inhibi-
tion of ERK1/2 activity may prevent the activation of
prosurvival pathways or could further limit anti-
proliferative effects. Such experiments could be per-
formed in human cell lines and xenograft models, but
also in accurate mouse models of SCLC in which
autochthonous tumors grow in the lung microenviro-
ment.78 Importantly, in all cases, phosphorylation of
ERK1/2 could serve as a simple biomarker to help
predict whether ERK1/2 inhibition might be clinically
relevant; however, each combination therapy partner
may necessitate its own biomarker to more efﬁciently
deﬁne the population of patients with SCLC who will
beneﬁt from this personalized approach. As potent and
speciﬁc inhibitors of the RAF/MEK/ERK pathway
continue to be developed and tested in other cancers,
allowing less toxic combination therapies to be efﬁca-
cious, it is possible that some of these molecules may be
useful in at least a subset of patients with SCLC.
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